Monitor for topline results from the TibuSURE trial in the first half of 2027, which could be a significant catalyst. The recent insider buying of $12.5M suggests confidence in the company's pipeline despite this being a neutral disclosure.
Price Chart
Executive Summary
Zura Bio Ltd announced that the design of its Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the 9th Systemic Sclerosis World Congress. The trial is evaluating dual inhibition of IL-17A and BAFF in diffuse cutaneous systemic sclerosis, with topline results expected in the first half of 2027.
Key Facts
- Zura Bio is presenting the design of its Phase 2 TibuSURE trial at the Systemic Sclerosis World Congress
- The trial evaluates tibulizumab (ZB-106), an investigational bispecific antibody targeting IL-17A and BAFF
- The study will enroll approximately 80 adults with diffuse cutaneous systemic sclerosis
- Primary endpoint is change from baseline in modified Rodnan Skin Score at Week 24
- Topline results are anticipated in the first half of 2027
- No clinical efficacy or safety data will be presented at this conference
Financial Impact
No immediate financial impact - this is a trial design disclosure without clinical data
Risk Factors
- Clinical trials may not demonstrate efficacy or safety of tibulizumab
- Development timelines could be delayed
- Regulatory approval is uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-023806 |
| Document: tm268054d1_ex99-1.htm | 0001104659-26-023806 |
| Document: 0001104659-26-023806-index-headers.html | 0001104659-26-023806 |
| Document: 0001104659-26-023806-index.html | 0001104659-26-023806 |
| Document: 0001104659-26-023806.txt | 0001104659-26-023806 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 10w ago | 8-K | $5.68 $4.93 | ▼ −13.20% | ▼ −11.23% | $3.56 (−37.32%) |
Aug 11, 2026 10w ago | 8-K | $5.56 $5.71 | ▲ +2.70% | ▲ +3.76% | $3.56 (−35.97%) |
Jul 1, 2026 16w ago | 8-K | $5.01 $5.31 | ▲ +6.09% | ▲ +8.28% | $3.56 (−28.87%) |
Jun 18, 2026 18w ago | 8-K | $4.23 $5.45 | ▲ +28.84% | ▲ +28.99% | $3.56 (−15.84%) |
May 7, 2026 24w ago | 8-K | $4.54 $3.86 | ▼ −14.98% | ▼ −18.11% | $3.56 (−21.59%) |
Mar 5, 2026 33w ago | 8-K | $6.76 $6.03 | ▼ −10.80% | ▼ −7.01% | $3.56 (−47.34%) |
Feb 26, 2026 34w ago | 8-K | $6.77 $6.04 | ▼ −10.78% | ▼ −4.38% | $3.56 (−47.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers